Michele Simonato

List of Publications by Year
in descending order

#	Article	IF	Citations
1	Gene networks and microRNAs: Promises and challenges for treating epilepsies and their comorbidities. Epilepsy and Behavior, 2021, 121, 106488.	1.7	4
2	Identification of clinically relevant biomarkers of epileptogenesis â€” a strategic roadmap. Nature Reviews Neurology, 2021, 17, 231-242.	10.1	54
3	Absence of RNAâ€binding protein FXR2P prevents prolonged phase of kainateâ€induced seizures. EMBO Reports, 2021, 22, e51404.	4.5	4
4	<i>SREBP2</i> gene therapy targeting striatal astrocytes ameliorates Huntingtonâ€™s disease phenotypes. Brain, 2021, 144, 3175-3190.	7.6	17
5	Improvement of HSV-1 based amplicon vectors for a safe and long-lasting gene therapy in non-replicating cells. Molecular Therapy - Methods and Clinical Development, 2021, 21, 399-412.	4.1	2
6	Antipsychotic drugs counteract autophagy and mitophagy in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	40
7	Anti-epileptogenic effect of NRP2945 in the pilocarpine model of temporal lobe epilepsy. European Journal of Pharmacology, 2021, 901, 174068.	3.5	2
8	I06â€...SREBP2 delivery to striatal astrocytes normalizes transcription of cholesterol biosynthesis genes and ameliorates pathological features in huntingtonâ€™s disease. , 2021, , .		0
9	Implication of sestrin3 in epilepsy and its comorbidities. Brain Communications, 2021, 3, fcaa130.	3.3	5
10	Meeting report: EpiXchange II brings together European epilepsy research projects to discuss latest advances. Epilepsy Research, 2021, 178, 106811.	1.6	1
11	NPY and Gene Therapy for Epilepsy: How, When,... and Y. Frontiers in Molecular Neuroscience, 2020, 13, 608001.	2.9	23
12	Gene Therapy Tools for Brain Diseases. Frontiers in Pharmacology, 2019, 10, 724.	3.5	131
13	Long-Term, Targeted Delivery of GDNF from Encapsulated Cells Is Neuroprotective and Reduces Seizures in the Pilocarpine Model of Epilepsy. Journal of Neuroscience, 2019, 39, 2144-2156.	3.6	29
14	Advancing research toward faster diagnosis, better treatment, and end of stigma in epilepsy. Epilepsia, 2019, 60, 1281-1292.	5.1	17
15	2017 WONOEP appraisal: Studying epilepsy as a network disease using systems biology approaches. Epilepsia, 2019, 60, 1045-1053.	5.1	12
16	A Matter of Genes: The Hurdles of Gene Therapy for Epilepsy. Epilepsy Currents, 2019, 19, 38-43.	0.8	11
17	Unilateral ex vivo gene therapy by GDNF in epileptic rats. Gene Therapy, 2019, 26, 65-74.	4.5	12
18	Personalized Needles for Microinjections in the Rodent Brain. Journal of Visualized Experiments, 2018, , .	0.3	1

#	Article	IF	Citations
19	Seizure-Suppressant and Neuroprotective Effects of Encapsulated BDNF-Producing Cells in a Rat Model of Temporal Lobe Epilepsy. Molecular Therapy - Methods and Clinical Development, 2018, 9, 211-224.	4.1	59
20	Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats. Journal of Visualized Experiments, 2018, , .	0.3	1
21	Discovery and validation of blood micro<scp>RNA</scp>s as molecular biomarkers of epilepsy: Ways to close current knowledge gaps. Epilepsia Open, 2018, 3, 427-436.	2.4	32
22	From fix to fit into the autoptic human brains. European Journal of Histochemistry, 2018, 62, .	1.5	5
23	Neurotrophic factors and status epilepticus. Epilepsia, 2018, 59, 87-91.	5.1	9
24	Cellular Antisilencing Elements Support Transgene Expression from Herpes Simplex Virus Vectors in the Absence of Immediate Early Gene Expression. Journal of Virology, 2018, 92, .	3.4	12
25	New Tools for Epilepsy Therapy. Frontiers in Cellular Neuroscience, 2018, 12, 147.	3.7	9
26	Epilepsy an Update on Disease Mechanisms: The Potential Role of MicroRNAs. Frontiers in Neurology, 2018, 9, 176.	2.4	13
27	Common data elements and data management: Remedy to cure underpowered preclinical studies. Epilepsy Research, 2017, 129, 87-90.	1.6	35
28	Is autopsy tissue a valid control for epilepsy surgery tissue in micro<scp>RNA</scp> studies?. Epilepsia Open, 2017, 2, 90-95.	2.4	11
29	Engineered HSV vector achieves safe long-term transgene expression in the central nervous system. Scientific Reports, 2017, 7, 1507.	3.3	27
30	Effects of [Nphe¹, Arg¹⁴, Lys¹⁵] N/OFQ-NH₂ (UFP-101), a potent NOP receptor antagonist, on molecular, cellular and behavioural alterations associated with chronic mild stress. Journal of Psychopharmacology, 2017, 31, 691-703.	4.0	25
31	Deletion of the Virion Host Shut-off Gene Enhances Neuronal-Selective Transgene Expression from an HSV Vector Lacking Functional IE Genes. Molecular Therapy - Methods and Clinical Development, 2017, 6, 79-90.	4.1	14
32	WONOEP appraisal: Development of epilepsy biomarkersâ€"What we can learn from our patients?. Epilepsia, 2017, 58, 951-961.	5.1	13
33	Standardization procedure for plasma biomarker analysis in rat models of epileptogenesis: Focus on circulating microRNAs. Epilepsia, 2017, 58, 2013-2024.	5.1	45
34	Cell Therapy for Epilepsy. Molecular and Translational Medicine, 2017, , 85-97.	0.4	0
35	eIF4B phosphorylation at Ser504 links synaptic activity with protein translation in physiology and pathology. Scientific Reports, 2017, 7, 10563.	3.3	14
36	Harmonization in preclinical epilepsy research: A joint AES/ILAE translational initiative. Epilepsia, 2017, 58, 7-9.	5.1	15

#	Article	IF	Citations
37	Identification and characterization of outcome measures reported in animal models of epilepsy: Protocol for a systematic review of the literatureâ€"A <scp>TASK</scp>2 report of the <scp>AES</scp>/<scp>ILAE</scp> Translational Task Force of the ILAE. Epilepsia, 2017, 58, 68-77.	5.1	8
38	Meta-Analysis of MicroRNAs Dysregulated in the Hippocampal Dentate Gyrus of Animal Models of Epilepsy. ENeuro, 2017, 4, ENEURO.0152-17.2017.	1.9	23
39	Silencing Status Epilepticus-Induced BDNF Expression with Herpes Simplex Virus Type-1 Based Amplicon Vectors. PLoS ONE, 2016, 11, e0150995.	2.5	8
40	Unverrichtâ€Lundborg disease. Epileptic Disorders, 2016, 18, 28-37.	1.3	46
41	Advances in the development of biomarkers for epilepsy. Lancet Neurology, The, 2016, 15, 843-856.	10.2	283
42	Opportunities for improving animal welfare in rodent models of epilepsy and seizures. Journal of Neuroscience Methods, 2016, 260, 2-25.	2.5	93
43	MicroRNA profiles in hippocampal granule cells and plasma of rats with pilocarpine-induced epilepsy â€" comparison with human epileptic samples. Scientific Reports, 2015, 5, 14143.	3.3	101
44	Systems genetics identifies Sestrin 3 as a regulator of a proconvulsant gene network in human epileptic hippocampus. Nature Communications, 2015, 6, 6031.	12.8	158
45	Gene Therapy for Neurological Diseases. , 2015, , 129-146.		0
46	Increased extracellular levels of glutamate in the hippocampus of chronically epileptic rats. Neuroscience, 2015, 301, 246-253.	2.3	36
47	<scp>WONOEP</scp> appraisal: New genetic approaches to study epilepsy. Epilepsia, 2014, 55, 1170-1186.	5.1	13
48	Impairment of GABA release in the hippocampus at the time of the first spontaneous seizure in the pilocarpine model of temporal lobe epilepsy. Experimental Neurology, 2014, 257, 39-49.	4.1	44
49	Gene therapy for epilepsy. Epilepsy and Behavior, 2014, 38, 125-130.	1.7	42
50	The challenge and promise of anti-epileptic therapy development in animal models. Lancet Neurology, The, 2014, 13, 949-960.	10.2	101
51	Identification of miRNAs Differentially Expressed in Human Epilepsy with or without Granule Cell Pathology. PLoS ONE, 2014, 9, e105521.	2.5	36
52	Proposal for a â€œphase <scp>II</scp>â€• multicenter trial model for preclinical new antiepilepsy therapy development. Epilepsia, 2013, 54, 70-74.	5.1	19
53	Increased excitability in tat-transgenic mice: Role of tat in HIV-related neurological disorders. Neurobiology of Disease, 2013, 55, 110-119.	4.4	37
54	Bradykinin B2 receptors increase hippocampal excitability and susceptibility to seizures in mice. Neuroscience, 2013, 248, 392-402.	2.3	17

#	Article	IF	Citations
55	Progress in gene therapy for neurological disorders. Nature Reviews Neurology, 2013, 9, 277-291.	10.1	202
56	Issues for new antiepilepsy drug development. Current Opinion in Neurology, 2013, 26, 195-200.	3.6	23
57	Joint <scp>AES</scp>/<scp>ILAE</scp> translational workshop to optimize preclinical epilepsy research. Epilepsia, 2013, 54, 1-2.	5.1	28
58	Changes in the sensitivity of GABAA current rundown to drug treatments in a model of temporal lobe epilepsy. Frontiers in Cellular Neuroscience, 2013, 7, 108.	3.7	21
59	Implication of fibroblast growth factors in epileptogenesis-associated circuit rearrangements. Frontiers in Cellular Neuroscience, 2013, 7, 152.	3.7	15
60	Nociceptin/Orphanin FQ Receptor Agonists Attenuate L-DOPA-Induced Dyskinesias. Journal of Neuroscience, 2012, 32, 16106-16119.	3.6	39
61	Bystander Effect on Brain Tissue of Mesoangioblasts Producing Neurotrophins. Cell Transplantation, 2012, 21, 1613-1627.	2.5	3
62	Finding a better drug for epilepsy: Antiepileptogenesis targets. Epilepsia, 2012, 53, 1868-1876.	5.1	82
63	Finding a better drug for epilepsy: Preclinical screening strategies and experimental trial design. Epilepsia, 2012, 53, 1860-1867.	5.1	69
64	Identification of new epilepsy treatments: Issues in preclinical methodology. Epilepsia, 2012, 53, 571-582.	5.1	219
65	Loss of cortical GABA terminals in Unverrichtâ€“Lundborg disease. Neurobiology of Disease, 2012, 47, 216-224.	4.4	42
66	Localized overexpression of FGF-2 and BDNF in hippocampus reduces mossy fiber sprouting and spontaneous seizures up to 4â€ƒweeks after pilocarpine-induced status epilepticus. Epilepsia, 2011, 52, 572-578.	5.1	63
67	Evaluation of cell damage in organotypic hippocampal slice culture from adult mouse: A potential model system to study neuroprotection. Brain Research, 2011, 1385, 68-76.	2.2	41
68	Brain Interstitial Nociceptin/Orphanin FQ Levels are Elevated in Parkinson's Disease. Movement Disorders, 2010, 25, 1723-1732.	3.9	37
69	The biocompatibility of materials used in printed circuit board technologies with respect to primary neuronal and K562 cells. Biomaterials, 2010, 31, 1045-1054.	11.4	16
70	Are the neurotrophic factors a suitable therapeutic target for the prevention of epileptogenesis?. Epilepsia, 2010, 51, 48-51.	5.1	106
71	Enhancement of GABA _A -current run-down in the hippocampus occurs at the first spontaneous seizure in a model of temporal lobe epilepsy. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3180-3185.	7.1	49
72	Hippocampal FGF-2 and BDNF overexpression attenuates epileptogenesis-associated neuroinflammation and reduces spontaneous recurrent seizures. Journal of Neuroinflammation, 2010, 7, 81.	7.2	105

#	Article	IF	Citations
73	Localized delivery of fibroblast growth factorâ€“2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7191-7196.	7.1	134
74	Functional antagonism between nociceptin/orphanin FQ (N/OFQ) and corticotropin-releasing factor (CRF) in the rat brain: evidence for involvement of the bed nucleus of the stria terminalis. Psychopharmacology, 2008, 196, 523-531.	3.1	64
75	Adenosine receptor antagonists alter the stability of human epileptic GABA _A receptors. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 15118-15123.	7.1	41
76	FGF-2 Overexpression Increases Excitability and Seizure Susceptibility but Decreases Seizure-Induced Cell Loss. Journal of Neuroscience, 2008, 28, 13112-13124.	3.6	33
77	GABA _A -current rundown of temporal lobe epilepsy is associated with repetitive activation of GABA _A â€œphasicâ€• receptors. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20944-20948.	7.1	60
78	A pathogenetic hypothesis of Unverrichtâ€“Lundborg disease onset and progression. Neurobiology of Disease, 2007, 25, 675-685.	4.4	45
79	Angels and demons: neurotrophic factors and epilepsy. Trends in Pharmacological Sciences, 2006, 27, 631-638.	8.7	86
80	Synthesis and anticonvulsant activity of a class of 2-amino 3-hydroxypropanamide and 2-aminoacetamide derivatives. Bioorganic and Medicinal Chemistry, 2006, 14, 3263-3274.	3.0	17
81	What Is the Biological Significance of BDNF mRNA Targeting in the Dendrites?: Clues From Epilepsy and Cortical Development. Molecular Neurobiology, 2006, 33, 017-032.	4.0	50
82	Alterations in Seizure Susceptibility and in Seizure-induced Plasticity after Pharmacologic and Genetic Manipulation of the Fibroblast Growth Factor-2 System. Epilepsia, 2005, 46, 52-58.	5.1	23
83	BODIPYÂ®-conjugated neuropeptide Y ligands: new fluorescent tools to tag Y1, Y2, Y4 and Y5 receptor subtypes. British Journal of Pharmacology, 2005, 146, 1069-1081.	5.4	20
84	Blockade of Nociceptin/Orphanin FQ Transmission Attenuates Symptoms and Neurodegeneration Associated with Parkinson's Disease. Journal of Neuroscience, 2005, 25, 9591-9601.	3.6	116
85	Brain-Derived Neurotrophic Factor mRNA and Protein Are Targeted to Discrete Dendritic Laminas by Events That Trigger Epileptogenesis. Journal of Neuroscience, 2004, 24, 6842-6852.	3.6	130
86	Kainate seizures increase nociceptin/orphanin FQ release in the rat hippocampus and thalamus: a microdialysis study. Journal of Neurochemistry, 2004, 91, 30-37.	3.9	27
87	Autoradiographic analysis of rat brain kinin B1 and B2 receptors: Normal distribution and alterations induced by epilepsy. Journal of Comparative Neurology, 2003, 461, 506-519.	1.6	49
88	Changes in NPY-mediated modulation of hippocampal [3H]D-aspartate outflow in the kindling model of epilepsy. Synapse, 2003, 49, 116-124.	1.2	8
89	Mechanisms of action of CHF3381 in the forebrain. British Journal of Pharmacology, 2003, 139, 1333-1341.	5.4	7
90	Antinociceptive Activity of the N-Methyl-d-aspartate Receptor Antagonist N-(2-Indanyl)-glycinamide Hydrochloride (CHF3381) in Experimental Models of Inflammatory and Neuropathic Pain. Journal of Pharmacology and Experimental Therapeutics, 2003, 306, 804-814.	2.5	77

#	ARTICLE	IF	CITATIONS
91	On the Role of Somatostatin in Seizure Control: Clues from the Hippocampus. Reviews in the Neurosciences, 2003, 14, 285-301.	2.9	57
92	Delayed epileptogenesis in nociceptin/orphanin FQ-deficient mice. NeuroReport, 2003, 14, 825-827.	1.2	17
93	Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist. NeuroReport, 2002, 13, 2071-2074.	1.2	21
94	Anaphylactic shock and acute pulmonary edema after a single oral dose of acetazolamide. American Journal of Emergency Medicine, 2002, 20, 371-372.	1.6	36
95	Involvement of the Neuropeptide Nociceptin/Orphanin FQ in Kainate Seizures. Journal of Neuroscience, 2002, 22, 10030-10038.	3.6	36
96	Pro-nociceptin/orphanin FQ and NOP receptor mRNA levels in the forebrain of food deprived rats. Brain Research, 2002, 957, 354-361.	2.2	32
97	Somatostatin Release in the Hippocampus in the Kindling Model of Epilepsy. Journal of Neurochemistry, 2002, 74, 2497-2503.	3.9	22
98	Circadian differences in the individual sensitivity to opiate overdose. Critical Care Medicine, 2001, 29, 96-101.	0.9	27
99	Kindled seizure-evoked somatostatin release in the hippocampus. NeuroReport, 2000, 11, 3209-3212.	1.2	3
100	Different Patterns of Induction of Fibroblast Growth Factor-2 and Brain-Derived Neurotrophic Factor Messenger RNAs During Kindling Epileptogenesis, and Development of a Herpes Simplex Vector for Fibroblast Growth Factor-2 Gene Transfer in Vivo. Epilepsia, 2000, 41, S122-S126.	5.1	16
101	Gene transfer into neurones for the molecular analysis of behaviour: focus on herpes simplex vectors. Trends in Neurosciences, 2000, 23, 183-190.	8.6	61
102	Limbic seizures increase pronociceptin mRNA levels in the thalamic reticular nucleus. NeuroReport, 1999, 10, 541-546.	1.2	15
103	Different patterns of induction of FGF-2, FGF-1 and BDNF mRNAs during kindling epileptogenesis in the rat. European Journal of Neuroscience, 1998, 10, 955-963.	2.6	32
104	Timeâ€•and Regionâ€Specific Variations in Somatostatin Release Following Amygdala Kindling in the Rat. Journal of Neurochemistry, 1998, 70, 252-259.	3.9	7
105	Prostaglandin F_{2Î±}Is Required for NMDA Receptor-Mediated Induction of c-<i>fos</i>mRNA in Dentate Gyrus Neurons. Journal of Neuroscience, 1997, 17, 117-124.	3.6	36
106	DYNORPHIN AND EPILEPSY. Progress in Neurobiology, 1996, 50, 557-583.	5.7	79
107	Biotin deficiency facilitates kindling hyperexcitability in rats. NeuroReport, 1996, 7, 1745-1748.	1.2	9
108	Changes in [³H]â€UK14304 binding to Î±₂â€adrenoceptors in morphineâ€dependent guineaâ€pigs. British Journal of Pharmacology, 1995, 116, 3125-3132.	5.4	5

#	Article	IF	Citations
109	5â€Hydroxytryptamineâ€mediated effects of nicotine on endogenous GABA efflux from guineaâ€pig cortical slices. British Journal of Pharmacology, 1995, 116, 2724-2728.	5.4	14
110	Adenosine A1 receptors in the rat brain in the kindling model of epilepsy. European Journal of Pharmacology, 1994, 265, 121-124.	3.5	27
111	A Pathogenetic Hypothesis of Temporal Lobe Epilepsy. Pharmacological Research, 1993, 27, 216-226.	7.1	14
112	Differential expression of immediate early genes in the hippocampus in the kindling model of epilepsy. Molecular Brain Research, 1991, 11, 115-124.	2.3	103
113	Lack of excitatory amino acid-induced effects on calcium fluxes measured with45Ca2+ in rat cerebral cortex synaptosomes. Neurochemical Research, 1989, 14, 677-682.	3.3	8
114	Dose- and time-dependent hippocampal cholinergic lesions induced by ethylcholine mustard aziridinium ion: Effects of nerve growth factor, GM1 ganglioside, and vitamin E. Neurochemical Research, 1988, 13, 685-692.	3.3	25
115	Acetylcholine Content in Rat Brain Is Elevated by Status Epilepticus Induced by Lithium and Pilocarpine. Journal of Neurochemistry, 1987, 49, 944-951.	3.9	72